AstraZeneca and the US-based Absci Corporation have agreed to a $247 million deal for the development of an antibody to combat cancer. This collaboration is the most recent in a rapidly growing series of agreements featuring artificial intelligence and drug discovery.
The partnership seeks to use Absci’s AI technology for large-scale protein analysis in the search for a workable cancer treatment, which is Anglo-Swedish pharmaceutical company AstraZeneca’s primary emphasis.
This collaboration is another in a string of deals between large pharmaceutical corporations and up-and-coming AI companies to create new disease therapies and reduce development costs.
The founder and CEO of Absci, Sean McClain, stated that the use of engineering concepts in drug discovery increased the likelihood of success and shortened the time needed for development.
The agreement covers milestone payments, research and development financing, an upfront fee for Absci, and royalties on any product sales.
Absci is a Washington state-based company with an AI research facility in New York. It measures millions of interactions between proteins to produce exclusive data.
After that, it utilizes these to develop and confirm workable antibodies, which are proteins that target foreign objects within the body, using its generative AI model.
The specific type of cancer that the businesses intend to target has not been made public.
The deal is a component of AstraZeneca’s grandiose aspirations to swap out conventional chemotherapy for a novel class of tailored pharmaceuticals.
It declared the results of clinical studies for novel treatments for breast and lung cancers in October, calling the findings a “huge accomplishment.”
Puja Sapra, a senior vice-president at AstraZeneca who oversees biologics engineering research and development, called the partnership with Absci a “exciting opportunity” to leverage the business’s AI for antibody creation.
“Artificial intelligence is helping us find more and better biologics faster, while also increasing the variety of biologics we find,” Sapra stated. “We are integrating artificial intelligence (AI) into every step of our research and development process, both internally and through partnerships like ours with Absci.”
The development of anti-tumour medications through diverse technologies is an important area of collaboration between major multinational pharmaceutical firms and smaller, cutting-edge research organizations.
In September, US company Moderna and Germany’s Immatics reached an agreement that might be worth over $1.7 billion to develop cancer vaccines and treatments. The German company targets cancer-related proteins with a technique known as T-cell receptor technology.
